Table 2 Univariate and multivariate Cox regression analyses of clinical characteristics associated with overall survival
From: NORAD-sponged miR-378c alleviates malignant behaviors of stomach adenocarcinoma via targeting NRP1
Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
T stage (T3 and T4 and T2 vs. T1) | 430 | 10.412 (1.458–74.379) | 0.020 | 5.421 (0.685–42.884) | 0.109 |
N stage (N1 and N2 and N3 vs. N0) | 420 | 2.190 (1.474–3.253) | < 0.001 | 2.088 (1.173–3.718) | 0.012 |
M stage (M1 vs. M0) | 420 | 2.571 (1.553–4.258) | < 0.001 | 1.842 (0.992–3.420) | 0.053 |
Pathologic stage (Stage II and Stage III and Stage IV vs. Stage I) | 413 | 2.303 (1.276–4.157) | 0.006 | 0.936 (0.389–2.251) | 0.883 |
Gender (Male vs. Female) | 440 | 1.026 (0.747–1.409) | 0.875 | ||
Race (Black or African American and White vs. Asian) | 381 | 1.380 (0.894–2.129) | 0.146 | ||
Age (> 65 vs. < = 65) | 437 | 1.472 (1.080–2.005) | 0.014 | 1.570 (1.089–2.264) | 0.016 |
Histologic grade (G2 and G3 vs. G1) | 431 | 1.001 (0.319–3.138) | 0.999 | ||
Residual tumor (R1 and R2 vs. R0) | 383 | 3.064 (1.953–4.806) | < 0.001 | 2.006 (1.186–3.392) | 0.009 |
Reflux history (Yes vs. No) | 255 | 0.612 (0.326–1.148) | 0.126 | ||
Antireflux treatment (Yes vs. No) | 215 | 0.705 (0.404–1.231) | 0.219 | ||
H pylori infection (Yes vs. No) | 184 | 0.483 (0.194–1.202) | 0.118 | ||
Barretts esophagus (Yes vs. No) | 247 | 0.869 (0.353–2.141) | 0.761 | ||
hsa-miR-378c (High vs. Low) | 440 | 0.735 (0.542–0.995) | 0.046 | 0.803 (0.566–1.140) | 0.220 |